Literature DB >> 11072213

Cervical cancer screening in the Netherlands.

M van Ballegooijen1, R Hermens.   

Abstract

The Netherlands is among the European countries with low incidence and almost lowest mortality from cancer of the uterine cervix. Screening started around 1970, being a combination of local and regional invitational programmes and opportunistic screening. In 1996 screening activities have been structured to a new national and nationwide programme. The restructuring concerned the management and financing of the programme, organisation, target age-ranges and interval, follow-up of abnormal test results, and evaluation. At the moment short-term results of implementation of the new screening programme are becoming available. It will take many more years before long-term effects of the new programme will emerge.

Entities:  

Mesh:

Year:  2000        PMID: 11072213     DOI: 10.1016/s0959-8049(00)00317-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996.

Authors:  S Bulk; F J Van Kemenade; L Rozendaal; C J L M Meijer
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

2.  Cervix smear abnormalities: linking pathology data in female twins, their mothers and sisters.

Authors:  Jacqueline M Vink; Folkert J van Kemenade; Chris J L M Meijer; Mariel K Casparie; Gerrit A Meijer; Dorret I Boomsma
Journal:  Eur J Hum Genet       Date:  2010-08-18       Impact factor: 4.246

3.  Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate.

Authors:  N W J Bulkmans; S Bulk; M S Ottevanger; L Rozendaal; S M Hellenberg; F J van Kemenade; P J F Snijders; A J P Boeke; C J L M Meijer
Journal:  J Clin Pathol       Date:  2006-08-30       Impact factor: 3.411

4.  Familial cervical cancer: case reports, review and clinical implications.

Authors:  Margreet Zoodsma; Rolf H Sijmons; Elisabeth Ge de Vries; Ate Gj van der Zee
Journal:  Hered Cancer Clin Pract       Date:  2004-05-15       Impact factor: 2.857

5.  Patient satisfaction in treatment for cervical pathology.

Authors:  M T J Hendriksen; K W M VAN Delft; G L H Bremer; H J M M Mertens
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

6.  Treatment strategies in intermediate cervical neoplasia: Implications of radical surgery.

Authors:  K W M VAN Delft; H J M M Mertens
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

Review 7.  Population-based cancer screening programmes in low-income and middle-income countries: regional consultation of the International Cancer Screening Network in India.

Authors:  Sudha Sivaram; Gautam Majumdar; Douglas Perin; Ashrafun Nessa; Mireille Broeders; Elsebeth Lynge; Mona Saraiya; Nereo Segnan; Rengaswamy Sankaranarayanan; Preetha Rajaraman; Edward Trimble; Stephen Taplin; G K Rath; Ravi Mehrotra
Journal:  Lancet Oncol       Date:  2018-02       Impact factor: 41.316

8.  Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.

Authors:  I H-I Chow; C-H Tang; S-L You; C-H Liao; T-Y Chu; C-J Chen; C-A Chen; R-F Pwu
Journal:  Br J Cancer       Date:  2010-11-23       Impact factor: 7.640

9.  Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing.

Authors:  M Kocken; J Berkhof; F J van Kemenade; J A Louwers; A Zaal; M A E Nobbenhuis; G Kenter; P J F Snijders; C J L M Meijer; T J M Helmerhorst
Journal:  Br J Cancer       Date:  2012-02-14       Impact factor: 7.640

10.  Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands.

Authors:  S Bulk; J Berkhof; N W J Bulkmans; G D Zielinski; L Rozendaal; F J van Kemenade; P J F Snijders; C J L M Meijer
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.